Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued to investors on Wednesday. The firm set a “buy” rating on the biotechnology company’s stock.

A number of other research analysts also recently commented on the company. Jones Trading downgraded Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, April 11th. HC Wainwright reduced their price objective on Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Wells Fargo & Company decreased their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a report on Friday, March 21st. Scotiabank dropped their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a report on Friday, March 21st. Finally, Guggenheim reduced their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a research report on Wednesday, March 26th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Adaptimmune Therapeutics has an average rating of “Moderate Buy” and an average price target of $1.83.

Adaptimmune Therapeutics Trading Down 0.6 %

ADAP opened at $0.28 on Wednesday. Adaptimmune Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.48. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The stock has a market capitalization of $70.76 million, a PE ratio of -1.25 and a beta of 2.84. The firm’s fifty day moving average price is $0.33 and its 200 day moving average price is $0.54.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The company had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million. As a group, research analysts expect that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its position in shares of Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 28,526 shares during the last quarter. Two Sigma Advisers LP increased its stake in shares of Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 58,787 shares during the period. Two Sigma Investments LP increased its stake in shares of Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 19,146 shares during the period. Virtu Financial LLC raised its holdings in shares of Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 21,688 shares during the last quarter. Finally, LPL Financial LLC boosted its position in shares of Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after buying an additional 94,623 shares during the period. 31.37% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.